



ASX & Media Release

Update to Indicative Timetable for Entitlement Offer

Melbourne, Australia; 11 November 2020: Patrys Limited (ASX: PAB, “Patrys” or the **Company**), a therapeutic antibody development company, wishes to advise of the following correction in regards to the indicative timetable relating to the Entitlement Offer, as announced by the Company on 9 November 2020.

The allotment date for the Shares and New Options under the Entitlement Offer has been corrected from 16 December 2020 to **15 December 2020** and as a result, the follow-on dates after this date have also been moved forward by one day.

All other dates remain unchanged.

The Company notes that the Appendix 3B titled ‘Proposed issue of securities – PAB’ lodged with the ASX on 9 November 2020 is correct and reflects the revised timetable outlined below.

The revised timetable* for the Placement, Entitlement Offer and Share Top Up Facility is as follows:

Event	Date
Company announces Placement and Entitlement Offer and lodges Prospectus with ASX and ASIC for the Entitlement Offer	9 November 2020
Ex-date	11 November 2020
Record Date for the Entitlement Offer	12 November 2020
Settlement of the Placement Shares	13 November 2020
Allotment and Issue of the Placement shares	16 November 2020
Dispatch of Prospectus and Entitlement and Acceptance Form to Eligible Shareholders via the Offer Website	17 November 2020
Entitlement Offer opens	17 November 2020
Last day to extend the Closing Date of the Entitlement Offer	3 December 2020
Entitlement Offer closes	8 December 2020
Shares and New Options quoted on a deferred settlement basis	9 December 2020
Announcement of Results of Entitlement Offer	11 December 2020
Settlement of Entitlement Offer	15 December 2020
Allotment of Shares, Placement Options and New Options under the Entitlement Offer	15 December 2020
Normal trading of Shares, Placement Options and New Options issued under the Entitlement Offer expected to commence on ASX	16 December 2020
Dispatch of holding statements	17 December 2020



* Note: The timetable above is indicative only and may be subject to change without notice. The Company, with the consent of the Lead Manager, reserves the right, subject to the Corporations Act, ASX Listing Rules and other applicable laws to amend or vary any or all of the dates and times without notice. In particular, the Company reserves the right to extend the closing date of the Entitlement Offer, accept late applications (either generally or in particular cases) and to withdraw the Entitlement Offer without prior notice.

The commencement of quotation of Shares and New Options is subject to confirmation from the ASX.

-Ends-

This ASX release was authorised on behalf of the Patrys Board by:

James Campbell, Managing Director and CEO

For further information, please contact:

General enquiries

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Media enquiries:

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

Registered Office Address

Level 4, 100 Albert Road
South Melbourne VIC 3205

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at www.patrys.com.

About Patrys' deoxymab 3E10 platform:

Patrys' deoxymab platform is based on the deoxymab 3E10 antibody that was first identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). While most antibodies bind to cell surface markers, deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes. Cancer cells often have high levels of mutations and underlying deficiencies in the DNA repair mechanisms. For these reasons, the additional inhibition of the DNA repair processes by deoxymab 3E10 can kill cancer cells, but appears to have little impact on normal cells. As a single agent, deoxymab 3E10 has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumours.



Patrys has developed two humanised forms of deoxymab 3E10, both which have improved activity over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In a range of pre-clinical studies, PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumour explants, xenograft and orthotopic models. PAT-DX1 has been shown to cross the blood brain barrier, reduce tumour size, and increase survival in multiple animal models of brain cancer, other cancers, and cancer metastases. PAT-DX1 is tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of specific tumour antigens. Patrys believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells.

Patrys' rights to deoxymab 3E10 are part of a worldwide license to develop and commercialize a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University as anti-cancer and diagnostic agents. Five patents covering the unconjugated form of deoxymab 3E10 (and derivatives thereof) have already been granted (Europe, Japan, China, and 2 in the USA), and one patent covering nanoparticle conjugation has been granted (Australia).